Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes

Internal Medicine Journal

Volumn 47, Issue 10, 2017, Pages 1147-1153

  Zou, Yaowu ^a,b   Li, Xinde ^a   Wang, Can ^a   Wang, Jing ^a   Wang, Fei ^a   Ma, Lidan ^a   You, Wenjun ^c   Li, Changgui ^a  

^a QINGDAO UNIVERSITY   (China)

^b Department of Neurosurgery Heze Hospital of Traditional Chinese Medicine   (China)

^c Jining First People's Hospital   (China)

Author keywords

non alcoholic fatty liver disease; peripheral artery disease; type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEPATOGRAPHY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; AGED; BLOOD; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PROCEDURES; QUESTIONNAIRE;

AGED; ANKLE BRACHIAL INDEX; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 85030678594     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.13549     Document Type: Article

References (36)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.
2. Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol 2014; 29: 42–51.
3. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metabol 2015; 100: 2231–8.
4. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59: 713–23.
5. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34: 1139–44.
6. Ying I, Ray JG. Nonalcoholic fatty liver disease and acute ischemic stroke. Epidemiology 2011; 22: 129–30.
7. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65: 589–600.
8. Pande RT, Perlstein TS, Beckman JA. Secondary prevention and mortality in peripheral artery disease: national health and nutrition examination study, 1999 to 2004. Circulation 2011; 124: 17–23.
9. Belch J, Maccuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: 1358.
10. Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease. J Am Coll Cardiol 2016; 67: 1338–57.
11. Lahoz C, Vicente I, Laguna F, García-Iglesias MF, Taboada M, Mostaza JM. Metabolic syndrome and asymptomatic peripheral artery disease in subjects over 60 years of age. Diabetes Care 2006; 29: 148–50.
12. Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004. Circulation 2008; 118: 33–41.
13. Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol 2013; 19: 6453–7.
14. Aronow WS. Nonalcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis. Future Cardiol 2016; 12: 393–6.
15. Li YM, Fan JG, Wang BY, Lu LG, Shi JP, Niu JQ et al. Guidelines for the diagnosis and management of alcoholic liver disease: update 2010. J Dig Dis 2011; 12: 45–50.
16. Gao X, Fan J-G, Study Group of Liver and Metabolism, Chinese Society of Endocrinology. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J. Diabetes 2013; 5: 406–15.
17. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51: 1947–53.
18. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009; 40: 571–5.
19. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541–6.
20. Garg PK, Biggs ML, Carnethon M, Ix JH, Criqui MH, Britton KA et al. Metabolic syndrome and risk of incident peripheral artery disease: the cardiovascular health study. Hypertension 2014; 63: 413–19.
21. Liu Y, Liu C, Shi X, Lin M, Yan B, Zeng X et al. Correlations of non-alcoholic fatty liver disease and serum uric acid with subclinical atherosclerosis in obese Chinese adults. J Diabetes 2017; 9: 586–95.
22. Dimova R, Tankova T, Guergueltcheva V, Tournev I, Chakarova N, Grozeva G et al. Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance. J Diabetes Complications 2017; 31: 537–43.
23. Hoe J, Koh WP, Jin A, Sum CF, Lim SC, Tavintharan S. Predictors of decrease in ankle–brachial index among patients with diabetes mellitus. Diabet Med 2012; 29: e304–7.
24. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43.
25. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391–7.
26. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004; 27: 889–94.
27. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009; 39: 437–44.
28. Lim S, Oh TJ, Koh KK. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 2015; 201: 408–14.
29. Kim HJ, Lim CW, Lee JH, Park HB, Suh Y, Cho YH et al. Gender-based differences in the relationship between fatty liver disease and atherosclerosis. Cardiovasc J Afr 2016; 27: 1–6.
30. Kim K-S, Oh H-J, Kim D-J, Kim S-K, Park SW, Cho Y-W et al. The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels. Endocr J 2013; 60: 1295–301.
31. Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 2004; 145: 1842.
32. Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ et al. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science 1999; 286: 2328.
33. Erkan G, Yilmaz G, Konca Degertekin C, Akyol G, Ozenirler S. Presence and extent of estrogen receptor-alpha expression in patients with simple steatosis and NASH. Pathol Res Pract 2013; 209: 429–32.
34. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–11.
35. Meyer MR, Fredette NC, Howard TA, Hu C, Ramesh C, Daniel C et al. G protein-coupled estrogen receptor protects from atherosclerosis. Sci Rep 2014; 4: 7564.
36. Babb RR. Nonalcoholic fatty liver disease. N Engl J Med 2002; 347: 768–9.